DRTB-HDT – Stratified host-directed therapy for drug-resistant tuberculosis: a randomized controlled multi-centre trial

Clinical trial of host-directed therapy for drug-resistant tuberculosis

Tuberculosis (TB) is a leading causes of morbidity and mortality worldwide. Current TB treatments are long, complex and often poorly tolerated; moreover, cases of the rifampicin-resistant (RIF-R) form of TB magnify this global health threat. The EU-funded DRTB-HDT project will determine if two adjunctive host-directed therapies can prevent the poor outcomes of treatment in cases of RIF-R TB. Patients with RIF-R TB and risk factors for poor outcome will participate in a randomised, controlled, three-armed multicentre trial. All patients will receive standard multidrug therapy; the experimental arms will additionally receive either CC-11050 or metformin. These selected drug candidates represent two complementary host-directed therapy strategies: reducing inflammation or inducing host cell anti-microbial activity, respectively. If the trial is a success, DRTB-HDT will improve the capacity to control RIF-R TB, thereby increasing the likelihood of its cure.



Supported by BayFOR:

Research Focus:

  • Medicine and Health

Project Coordination:

Swiss Tropical and Public Health Institute
(Swiss THP)

Project Partner:

Instituto Nacional de Saúde
Ludwig-Maximilians-Universität Munich
The Aurum Institute
WITS Health Consortium (PTY) LTD


South Africa, Mozambique, Germany (Bavaria)

Funding Agency:

European Union

Funding Type: